NC
GENE

NewSquare Capital’s Genetic Technologies Ltd. GENE Stock Holding History

NewSquare Capital’s Portfolio GENE Stock Details GENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-20
Closed -$83 – 928
2023
Q2 		$83 Buy
+20
New +$99 ﹤0.01% 802

Other funds holding GENE

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SA
Scarborough Advisors Annapolis, Maryland $871M AUM 21.96% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
PWA
Provenance Wealth Advisors Fort Lauderdale, Florida $1.05B AUM 18.67% 1-Year Est. Return

NewSquare Capital's GENE Position: Q3 2023 in Review

NewSquare Capital sold out of Genetic Technologies Ltd. (GENE) in Q3 2023, closing a stake of 20 shares — an estimated $83 sold.

NewSquare Capital first reported a position in GENE in Q2 2023 and held it in 1 quarter. The position peaked at $83 in Q2 2023. 6 funds tracked by Wall St. Rank hold GENE as of Q3 2023.

  • NewSquare Capital reported no remaining Genetic Technologies Ltd. position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 20 Genetic Technologies Ltd. shares in Q3 2023, an estimated $83.
  • NewSquare Capital first reported a position in Genetic Technologies Ltd. in Q2 2023 and held it in 1 quarter.
  • NewSquare Capital's Genetic Technologies Ltd. position peaked at $83 in Q2 2023.
  • 6 funds tracked by Wall St. Rank held Genetic Technologies Ltd. as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.